[go: up one dir, main page]

MX2017012460A - Composiciones y metodos para el tratamiento de la anemia. - Google Patents

Composiciones y metodos para el tratamiento de la anemia.

Info

Publication number
MX2017012460A
MX2017012460A MX2017012460A MX2017012460A MX2017012460A MX 2017012460 A MX2017012460 A MX 2017012460A MX 2017012460 A MX2017012460 A MX 2017012460A MX 2017012460 A MX2017012460 A MX 2017012460A MX 2017012460 A MX2017012460 A MX 2017012460A
Authority
MX
Mexico
Prior art keywords
anemia
compositions
methods
treating anemia
kidney disease
Prior art date
Application number
MX2017012460A
Other languages
English (en)
Other versions
MX374909B (es
Inventor
Smith Alexander
Ajay CHANDORKAR Gurudatt
Ikpong Ette Ene
John Maroni Bradley
Suzanne HARTMAN Charlotte
Farzaneh-Far Ramin
Kern INRIG Jula
Original Assignee
Akebia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57006457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017012460(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akebia Therapeutics Inc filed Critical Akebia Therapeutics Inc
Publication of MX2017012460A publication Critical patent/MX2017012460A/es
Publication of MX374909B publication Critical patent/MX374909B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Dosis específicas de y regímenes de dosificación para, por el uso de un inhibidor de prolil hidroxilasa de HIF en el tratamiento o la prevención de la anemia, tal como la anemia secundaria a o asociada con la enfermedad renal crónica, la anemia secundaria a o asociada con la enfermedad renal crónica no dependiente de diálisis, la anemia asociada o que resulta de la quimioterapia o la anemia asociada con el SIDA.
MX2017012460A 2015-04-01 2016-03-31 El uso del inhibidor de propil hidrolasa del factor inducible de hipoxia (hif) para el tratamiento o prevención de la anemia. MX374909B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562141420P 2015-04-01 2015-04-01
US201562270168P 2015-12-21 2015-12-21
PCT/US2016/025235 WO2016161094A1 (en) 2015-04-01 2016-03-31 Compositions and methods for treating anemia

Publications (2)

Publication Number Publication Date
MX2017012460A true MX2017012460A (es) 2018-01-30
MX374909B MX374909B (es) 2025-03-06

Family

ID=57006457

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017012460A MX374909B (es) 2015-04-01 2016-03-31 El uso del inhibidor de propil hidrolasa del factor inducible de hipoxia (hif) para el tratamiento o prevención de la anemia.
MX2020009415A MX386796B (es) 2015-04-01 2016-03-31 El uso del inhibidor de propil hidrolasa del factor inducible de hipoxia (hif) para el tratamiento o prevencion de la anemia
MX2021012155A MX2021012155A (es) 2015-04-01 2017-09-28 Composiciones y metodos para el tratamiento de la anemia.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2020009415A MX386796B (es) 2015-04-01 2016-03-31 El uso del inhibidor de propil hidrolasa del factor inducible de hipoxia (hif) para el tratamiento o prevencion de la anemia
MX2021012155A MX2021012155A (es) 2015-04-01 2017-09-28 Composiciones y metodos para el tratamiento de la anemia.

Country Status (35)

Country Link
US (3) US11324734B2 (es)
EP (2) EP3995138A1 (es)
JP (4) JP6929785B2 (es)
KR (3) KR102647879B1 (es)
CN (2) CN107645953B (es)
AU (3) AU2016243700B2 (es)
BR (1) BR112017021097B1 (es)
CL (2) CL2017002456A1 (es)
CO (1) CO2017011200A2 (es)
CR (2) CR20170450A (es)
CU (1) CU20170126A7 (es)
CY (1) CY1124869T1 (es)
DK (1) DK3277270T3 (es)
EA (1) EA036920B1 (es)
EC (1) ECSP17073209A (es)
ES (1) ES2900481T3 (es)
HR (1) HRP20211862T1 (es)
HU (1) HUE056958T2 (es)
IL (3) IL292262B2 (es)
LT (1) LT3277270T (es)
MA (1) MA41863A (es)
MX (3) MX374909B (es)
MY (1) MY192705A (es)
NZ (1) NZ735973A (es)
PE (1) PE20180189A1 (es)
PH (1) PH12017501789B1 (es)
PL (1) PL3277270T3 (es)
PT (1) PT3277270T (es)
SA (1) SA517390054B1 (es)
SG (1) SG11201707994UA (es)
SI (1) SI3277270T1 (es)
TW (4) TWI718138B (es)
UA (1) UA123308C2 (es)
WO (1) WO2016161094A1 (es)
ZA (2) ZA201706681B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3357911T (pt) 2006-06-26 2022-07-11 Akebia Therapeutics Inc Inibidores da prolil-hidroxilase e métodos de utilização
NO2686520T3 (es) 2011-06-06 2018-03-17
EP3007695B1 (en) 2013-06-13 2024-02-07 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
CR20160222U (es) 2013-11-15 2016-08-26 Akebia Therapeutics Inc Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
CA2974691A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
UA123308C2 (uk) 2015-04-01 2021-03-17 Екебіа Терапьютікс, Інк. Композиції і способи для лікування анемії
JP6864834B2 (ja) * 2017-06-14 2021-04-28 ニプロ株式会社 投与量決定プログラムおよび投与量決定装置
WO2019028150A1 (en) 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
JP7440989B2 (ja) 2018-05-09 2024-02-29 アケビア セラピューティクス インコーポレイテッド ２－［５－（３－クロロフェニル）－３－ヒドロキシピリジン－２－カルボニル］アミノ］酢酸を調製するための方法
PH12022551040A1 (en) * 2019-10-31 2023-05-29 Akebia Therapeutics Inc Therapeutic methods using vadadustat
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
EP4121009A4 (en) * 2020-03-17 2024-04-17 Zydus Lifesciences Limited Formulation comprising hif prolyl hydroxylase inhibitors
CA3181403A1 (en) * 2020-04-29 2021-11-04 BioAge Labs, Inc. Hypoxia-inducible factor prolyl hydroxylase inhibitors for treating aging-related conditions
US20230225977A1 (en) * 2020-06-19 2023-07-20 Glaxosmithkline Intellectual Property (No.2) Limited Formulation comprising daprodustat
KR20230027157A (ko) * 2020-06-19 2023-02-27 아케비아 테라퓨틱스 인코포레이티드 바다두스타트의 약물-약물 상호작용의 조절
US20220034871A1 (en) * 2020-07-31 2022-02-03 Daiichi Sankyo Company, Limited Methods for administering pexidartinib
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
AU2022206302A1 (en) * 2021-01-08 2023-08-17 Akebia Therapeutics, Inc. Therapeutic methods using vadadustat
IL305487A (en) 2021-03-01 2023-10-01 Akebia Therapeutics Inc Modulation of drug-drug interactions by VADADUSTAT
WO2025087208A1 (zh) * 2023-10-24 2025-05-01 杭州安道药业有限公司 缺氧诱导因子-脯酰胺羟基化酶抑制剂(hif-phi)在罕见贫血中的应用

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655679A (en) 1969-06-25 1972-04-11 Merck & Co Inc Certain aryl pyridine carboxylic acid derivatives
US3703582A (en) 1970-04-20 1972-11-21 Merck & Co Inc Aryl pyridine carboxylic acids in the treatment of inflammation
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
CA1261335A (en) 1984-08-29 1989-09-26 Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee Ethylenediamine monoamide derivatives
CN1023479C (zh) 1985-09-27 1994-01-12 弗·哈夫曼-拉罗切有限公司 乙二胺的单酰胺衍生物的制备方法
TW219933B (es) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (de) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
ES2101421T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
DK0650960T3 (da) 1993-11-02 1997-09-01 Hoechst Ag Substituerede heterocykliske carboxylsyreamid-estere, deres fremstilling og deres anvendelse som lægemidler.
TW406076B (en) 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
CA2253282A1 (en) 1996-04-30 1997-11-06 Hoechst Aktiengesellschaft 3-alkoxypyridine-2-carboxylic acid amide esters, their preparation and their use as drugs
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
US6420427B1 (en) 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
AU757868B2 (en) 1998-03-23 2003-03-06 Aventis Pharmaceuticals Inc. Piperididinyl and N-amidinopiperidinyl derivatives
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
DK1265608T3 (da) 2000-03-22 2008-12-08 Pharmacia & Upjohn Co Llc Oxazolidinon tabletformulering
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
AU2002241154A1 (en) 2001-03-21 2002-10-03 Isis Innovation Ltd. Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
SE0101327D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
CN102552261A (zh) 2001-12-06 2012-07-11 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
NZ536908A (en) 2002-05-17 2008-09-26 Celgene Corp Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient
MXPA05002245A (es) 2002-08-29 2005-06-08 Merck & Co Inc Derivados de n-biarilmetil aminocicloalcancarboxamida.
PL376770A1 (pl) 2002-10-16 2006-01-09 Isis Innovation Limited Hydroksylazy asparaginylowe i ich modulatory
CA2506799A1 (en) 2002-11-21 2004-06-10 Eli Lilly And Company Mixed lineage kinase modulators
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
US20060251638A1 (en) 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
CA2528232C (en) 2003-06-06 2010-05-25 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
WO2005108370A1 (ja) 2004-04-16 2005-11-17 Ajinomoto Co., Inc. ベンゼン化合物
US20080113383A1 (en) 2004-05-28 2008-05-15 Fibro Gen, Inc. Hif Prolyl Hydroxylase Activity Assay
WO2005115984A2 (en) 2004-05-31 2005-12-08 Tanabe Seiyaku Co., Ltd. Large conductance calcium-activitated k channel opener
KR20070083484A (ko) 2004-07-14 2007-08-24 피티씨 테라퓨틱스, 인크. Ｃ형 간염 치료 방법
TW200616969A (en) 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
AU2005325930B2 (en) * 2005-01-27 2012-01-19 Alembic Limited Extended release formulation of Levetiracetam
WO2006084210A2 (en) 2005-02-04 2006-08-10 Regents Of The University Of California, San Diego Hif modulating compounds and methods of use thereof
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
JP5390184B2 (ja) 2005-06-06 2014-01-15 ファイブローゲン、インコーポレーテッド 貧血の改良された治療方法
US8530404B2 (en) 2005-06-15 2013-09-10 Fibrogen, Inc. Compounds and methods for treatment of cancer
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2007047194A2 (en) 2005-10-11 2007-04-26 Dana-Farber Cancer Institute, Inc. Methods for treating mitf-related disorders
JP5202327B2 (ja) 2005-12-09 2013-06-05 アムジエン・インコーポレーテツド プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用
GB2453819A (en) 2006-01-09 2009-04-22 Btg Int Ltd Modulators of hypoxia inducible factor-1 and related uses
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
JP4801451B2 (ja) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
TW200738709A (en) 2006-01-19 2007-10-16 Osi Pharm Inc Fused heterobicyclic kinase inhibitors
ITMI20060179A1 (it) 2006-02-02 2007-08-03 Abiogen Pharma Spa Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
WO2007101204A1 (en) 2006-02-27 2007-09-07 Alcon Research, Ltd. Method of treating glaucoma
AR059733A1 (es) 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
ES2288117B1 (es) 2006-05-08 2008-12-01 Combino Pharm, S.L. Composicion farmaceutica solida de gabapentina.
WO2007136990A2 (en) 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
TWI394747B (zh) 2006-06-23 2013-05-01 Smithkline Beecham Corp 脯胺醯基羥化酶抑制劑
PT3357911T (pt) 2006-06-26 2022-07-11 Akebia Therapeutics Inc Inibidores da prolil-hidroxilase e métodos de utilização
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
JP2008201711A (ja) * 2007-02-20 2008-09-04 Ss Pharmaceut Co Ltd システイン臭が低減された固形製剤
US7569726B2 (en) 2007-04-18 2009-08-04 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
CA2683758A1 (en) 2007-04-18 2008-10-30 Merck & Co., Inc. Novel 1,8-naphthyridine compounds
EP2150251B9 (en) 2007-05-04 2013-02-27 Amgen, Inc Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
JP5349462B2 (ja) 2007-05-16 2013-11-20 メルク・シャープ・アンド・ドーム・コーポレーション スピロインダロン
CN101765596B (zh) 2007-05-18 2015-04-29 拜耳知识产权有限责任公司 用于治疗过增生症状和与血管生成有关疾病的缺氧诱导因子(hif)抑制剂
EP2186528B1 (en) 2007-08-06 2014-03-19 Senju Pharmaceutical Co., Ltd. Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
KR20100045480A (ko) 2007-08-10 2010-05-03 크리스탈지노믹스(주) 피리딘 유도체 및 이들의 사용방법
WO2009035534A2 (en) 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
US20100305154A1 (en) 2007-11-30 2010-12-02 Glaxosmithkline Llc Prolyl Hydroxylase Inhibitors
NZ585701A (en) 2007-11-30 2012-09-28 Glaxosmithkline Llc Benzopyrazine derivatives as prolyl hydroxylase inhibitors
EP2227475B1 (en) 2007-12-03 2014-02-19 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
WO2009086044A1 (en) 2007-12-19 2009-07-09 Smith Kline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009086592A1 (en) 2008-01-04 2009-07-16 Garvan Institute Of Medical Research Method of increasing metabolism
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
ES2546213T3 (es) 2008-03-03 2015-09-21 Novartis Ag Compuestos y composiciones como moduladores de la actividad de TLR
PE20110409A1 (es) 2008-07-23 2011-06-22 Hoffmann La Roche Compuestos heterociclicos antiviricos
BRPI0913485A2 (pt) 2008-09-15 2016-06-07 Kasina Laila Innova Pharmaceuticals Private Ltd medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres.
AU2009314155B2 (en) 2008-11-14 2015-10-08 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
RU2529868C2 (ru) 2009-03-31 2014-10-10 Кисcеи Фармасьютикал Ко., Лтд. Производное индолизина и его применение в медицинских целях
BR112012010766A2 (pt) 2009-11-06 2015-10-06 Aerpio Therapeutics Inc composições e métodos de tratamento da colite e de outras doenças instestinais
JO2978B1 (en) 2009-12-21 2016-03-15 ايلي ليلي اند كومباني MGLU2 aids
WO2012097331A1 (en) * 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing reticulocyte hemoglobin content
WO2012170442A1 (en) 2011-06-06 2012-12-13 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
NO2686520T3 (es) 2011-06-06 2018-03-17
WO2012174256A2 (en) 2011-06-17 2012-12-20 The Regents Of The University Of Michigan Dna methylation profiles in cancer
ES2606631T3 (es) 2011-07-22 2017-03-24 Beijing Betta Pharmaceuticals Co., Ltd Formas polimeróficas de compuestos como inhibidor de la prolila hidroxilasa, y usos de los mismos
WO2013070908A1 (en) 2011-11-09 2013-05-16 Fibrogen, Inc. Therapeutic method
JP2015537013A (ja) 2012-11-19 2015-12-24 アサンタ・アー／エス 速崩性錠剤
KR20160061911A (ko) * 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
ES2786924T3 (es) * 2013-06-06 2020-10-14 Fibrogen Inc Formulaciones farmacéuticas que comprenden un inhibidor de hidroxilasa del HIF
EP3007695B1 (en) 2013-06-13 2024-02-07 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
EP3032953A4 (en) 2013-08-16 2017-02-08 Ohio State Innovation Foundation Compositions and methods for modulating dna methylation
CR20160222U (es) 2013-11-15 2016-08-26 Akebia Therapeutics Inc Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
WO2015112831A1 (en) 2014-01-23 2015-07-30 Akebia Therapeutics, Inc. Compositions and methods for treating ocular diseases
US10617716B2 (en) 2014-12-16 2020-04-14 Urgo Us, Inc. Hypochlorous acid formulations and methods for treating skin conditions
CA2974691A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
AU2016235534A1 (en) 2015-03-20 2017-10-12 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
UA123308C2 (uk) 2015-04-01 2021-03-17 Екебіа Терапьютікс, Інк. Композиції і способи для лікування анемії

Also Published As

Publication number Publication date
JP6929785B2 (ja) 2021-09-01
TW202421140A (zh) 2024-06-01
CA2981176A1 (en) 2017-10-06
HK1248590A1 (zh) 2018-10-19
PL3277270T3 (pl) 2022-02-14
AU2020273282B2 (en) 2022-10-20
TW201642839A (zh) 2016-12-16
ES2900481T3 (es) 2022-03-17
US20180092892A1 (en) 2018-04-05
PH12017501789A1 (en) 2018-04-11
EP3277270B1 (en) 2021-10-27
IL305910B1 (en) 2024-12-01
PT3277270T (pt) 2021-12-07
AU2016243700B2 (en) 2020-08-20
JP2023093684A (ja) 2023-07-04
EP3995138A1 (en) 2022-05-11
TWI718138B (zh) 2021-02-11
HRP20211862T1 (hr) 2022-03-04
NZ735973A (en) 2023-06-30
IL254710A0 (en) 2017-11-30
CN107645953A (zh) 2018-01-30
NZ773901A (en) 2024-07-26
CR20210248A (es) 2021-06-01
US11844756B2 (en) 2023-12-19
PH12017501789B1 (en) 2024-02-16
CR20170450A (es) 2018-04-03
WO2016161094A1 (en) 2016-10-06
DK3277270T3 (da) 2021-12-06
TW202320770A (zh) 2023-06-01
JP2018510178A (ja) 2018-04-12
JP2021181478A (ja) 2021-11-25
BR112017021097A2 (pt) 2018-07-03
US20230071553A1 (en) 2023-03-09
TWI794725B (zh) 2023-03-01
JP2025069280A (ja) 2025-04-30
SI3277270T1 (sl) 2022-04-29
PE20180189A1 (es) 2018-01-23
AU2020273282A1 (en) 2020-12-17
IL292262B1 (en) 2023-10-01
CL2017002456A1 (es) 2018-04-20
KR20240038132A (ko) 2024-03-22
ZA202006107B (en) 2024-02-28
CY1124869T1 (el) 2022-11-25
IL254710B (en) 2022-05-01
AU2016243700A1 (en) 2017-10-26
MA41863A (fr) 2021-06-02
MX2020009415A (es) 2021-10-04
US11324734B2 (en) 2022-05-10
AU2023200252A1 (en) 2023-02-16
CU20170126A7 (es) 2018-07-05
KR20250150155A (ko) 2025-10-17
UA123308C2 (uk) 2021-03-17
CN115607521A (zh) 2023-01-17
MY192705A (en) 2022-09-02
JP7629049B2 (ja) 2025-02-12
IL305910B2 (en) 2025-04-01
IL292262A (en) 2022-06-01
AU2023200252B2 (en) 2025-03-20
MX2021012155A (es) 2022-08-02
CL2019001927A1 (es) 2019-11-29
BR112017021097B1 (pt) 2024-01-02
EA036920B1 (ru) 2021-01-15
KR20170132865A (ko) 2017-12-04
CO2017011200A2 (es) 2018-04-19
MX374909B (es) 2025-03-06
ZA201706681B (en) 2021-02-24
IL305910A (en) 2023-11-01
SA517390054B1 (ar) 2022-02-22
EA201792182A1 (ru) 2018-06-29
SG11201707994UA (en) 2017-10-30
TWI881714B (zh) 2025-04-21
MX386796B (es) 2025-03-19
US20240325361A1 (en) 2024-10-03
EP3277270A4 (en) 2018-10-31
TWI836883B (zh) 2024-03-21
IL292262B2 (en) 2024-02-01
LT3277270T (lt) 2022-01-10
ECSP17073209A (es) 2017-12-01
CN107645953B (zh) 2022-11-01
EP3277270A1 (en) 2018-02-07
JP7270688B2 (ja) 2023-05-10
TW202140001A (zh) 2021-11-01
HUE056958T2 (hu) 2022-04-28
KR102647879B1 (ko) 2024-03-15
KR102866021B1 (ko) 2025-09-30

Similar Documents

Publication Publication Date Title
CO2017011200A2 (es) Composiciones y métodos para el tratamiento de la anemia
ECSP20058592A (es) Composiciones y métodos para tratar anemia
EA201692285A8 (ru) Ингибиторы ezh2 для лечения лимфомы
BR112018013847A2 (pt) métodos para administrar a angiotensina ii
BR112019006504A2 (pt) regime de dosagem de avelumabe para o tratamento de câncer
AR104157A1 (es) Composiciones y métodos para el tratamiento de la anemia
CR20150660A (es) Composiciones y metodos para tratar anemia
BR112018070526A2 (pt) tratamento do carcinoma de células renais com lenvatinibe e everolimo
TW202602440A (zh) 用於治療貧血之組合物及方法

Legal Events

Date Code Title Description
FG Grant or registration